Alendronate treatment in children with osteogenesis imperfecta

Indian Pediatrics

Volumn 45, Issue 2, 2008, Pages 105-109

  Akcay, Teoman ^a   Turan, Serap ^a   Guran, Tulay ^a   Bereket, Abdullah ^a,b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Alendronate; Bisphosphanates; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; OSTEOCALCIN; PHOSPHORUS; VITAMIN D;

ADOLESCENT; AGE DISTRIBUTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HUMAN; MALE; OSTEOGENESIS IMPERFECTA; PHOSPHATE BLOOD LEVEL; SEX RATIO; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FRACTURES, BONE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; PREVALENCE; SEVERITY OF ILLNESS INDEX; VITAMIN D;

EID: 40349084107     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Paterson CR. Osteogenesis imperfecta and other heritable disorders of bone. Baillieres Clin Endocrinol Metab 1997; 11: 195-213.
2. Shapiro JR, Stover ML, Burn VE, McKinstry MB, Burshell AL, Chipman SD, et al. An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen. J Clin Invest 1992; 89: 567-573.
3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-116.
4. Spencer H, Kramer L, Wiatrowski E, Lender M. Fluoride therapy in metabolic bone disease. Isr J Med Sci 1984; 20: 373-380.
5. Dent CE, Davies IJ. Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol. J R Soc Med 1980; 73: 780-785.
6. Castells S. New approaches to treatment of osteogenesis imperfecta. Clin Orthop Relat Res 1973; 93: 239-249.
7. Kurz D, Eyring EJ. Effects of vitamin C on osteogenesis imperfecta. Pediatrics 1974; 54: 56-61.
8. Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996; 129: 432-439.
9. Castells S, Colbert C, Chakrabarti C, Bachtell RS, Kassner EG, Yasumura S. Therapy of osteogenesis imperfecta with synthetic salmon calcitonin. J Pediatr 1997; 95: 807-811.
10. Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD. Diphosphonates in the treatment of myositis ossificans. Lancet 1969; 2: 845.
11. Fleisch H. Bisphosphonates: mechanism of action. Endocrinol Rev 1998; 19: 80-100.
12. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Min Res 1997; 12: 1746-1752.
13. Licata AA. Bisphosphonate therapy. Am J Med Sci 1997; 313: 17-22.
14. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
15. Banerjee I, Shortland GJ, Evans WD, Gregory JW. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 2002; 87: 562-563.
16. McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 2002; 52: 660-670.
17. Brumsen C, Hamdy NA, Papapoulos SE. Longterm effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-283.
18. Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005; 18: 43-53.
19. Vyskocil V, Pikner R, Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 2005; 72: 416-423.
20. Allgrove J. Use of bisphosphonates in children and adolescents. J Pediatr Endocrinol Metab 2002; 15: 921-928.
21. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003; 33: 226-229.
22. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteoporosis. N Engl J Med 2003; 349: 457-463.
23. Marini JC. Do Bisphosphonates make children's bones better or brittle? N Engl J Med 2003; 349: 423-426.
24. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 2002; 110: 1239-1241.
25. Sholas MG, Tann B, Gaebler-Spira D. Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. J Pediatr Orthop 2005; 25: 326-331.